about
Can follicular helper T cells be targeted to improve vaccine efficacy?Systems Biology Approach for Cancer Vaccine Development and EvaluationMerozoite surface protein 1 recognition of host glycophorin A mediates malaria parasite invasion of red blood cellsInternational Consensus (ICON): allergic reactions to vaccinesProtein Crystallography in Vaccine Research and DevelopmentThe prevention and eradication of smallpox: a commentary on Sloane (1755) 'An account of inoculation'Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.A New Adjuvant MTOM Mediates Mycobacterium tuberculosis Subunit Vaccine to Enhance Th1-Type T Cell Immune Responses and IL-2+ T Cells.Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles.Blood-stage immunity to Plasmodium chabaudi malaria following chemoprophylaxis and sporozoite immunizationNew challenges in modern vaccinologyPD-1 deficiency enhances humoral immunity of malaria infection treatment vaccine.Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola VaccineNovel antigen delivery systems.The Anopheles-midgut APN1 structure reveals a new malaria transmission-blocking vaccine epitopeMF59- and Al(OH)3-Adjuvanted Staphylococcus aureus (4C-Staph) Vaccines Induce Sustained Protective Humoral and Cellular Immune Responses, with a Critical Role for Effector CD4 T Cells at Low Antibody Titers.Successive site translocating inoculation potentiates DNA/recombinant vaccinia vaccinationCell Wall Anchoring of the Campylobacter Antigens to Lactococcus lactis.Religious exception for vaccination or religious excuses for avoiding vaccination.Assessment of the adjuvant activity of mesoporous silica nanoparticles in recombinant Mycoplasma hyopneumoniae antigen vaccines.Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns.CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes.The assessment of Hantaan virus-specific antibody responses after the immunization program for hemorrhagic fever with renal syndrome in northwest China.Phase 3 Trial of a Sabin Strain-Based Inactivated Poliovirus Vaccine.Anti-Infectious Human Vaccination in Historical Perspective.Comparison of Current Regulatory Status for Gene-Based Vaccines in the U.S., Europe and Japan.Use of adjuvants for immunotherapy.Phage-displayed peptides that mimic epitopes of hepatitis E virus capsid.Cytomegalovirus (CMV) Infection Causes Degeneration of Cochlear Vasculature and Hearing Loss in a Mouse Model.Immune Response of A Novel ATR-AP205-001 Conjugate Anti-hypertensive Vaccine.Vaccine vectors based on Adenovirus 19a/64 exhibit broad cellular tropism and potently restimulate HCMV-specific T cell responses ex vivo.Crystal structure reveals vaccine elicited bactericidal human antibody targeting a conserved epitope on meningococcal fHbp.Modulating the immune system through nanotechnology.Protective humoral and CD4+ T cellular immune responses of Staphylococcus aureus vaccine MntC in a murine peritonitis model.Polymeric Nanocapsules for Vaccine Delivery: Influence of the Polymeric Shell on the Interaction With the Immune System.Quillaja brasiliensis saponin-based nanoparticulate adjuvants are capable of triggering early immune responses
P2860
Q26753848-AE988B6B-BF78-456E-869B-3325C3927D23Q26782580-DFA3BFEB-8C1E-4234-8D45-5512732C58B7Q27230075-44C441D6-84DB-4061-BDA9-6448B80588CCQ27468685-FB67CCD5-B65A-4219-B194-C73AA73451C3Q28087528-E5004C71-343B-42EA-A0A5-A398ADB065FFQ28088338-B1740614-725B-4F89-9B33-09FF3BC22D32Q30390832-FCDAB47F-102E-41D1-AEAD-19A736BD4F0DQ33703027-A88B9079-2802-4720-8288-8E1B5E7B98E7Q34600988-1CE99420-F54F-4DBB-B8E3-37108AFB8EA1Q35211003-56756A09-ED57-4A2A-92A6-E009FE55F31AQ35218614-BD5AB026-7CED-4845-B501-7448DFE41359Q35439757-597EFC6B-8D13-4B6C-9851-1B84D663CF3DQ35917496-8A699A92-A6C5-4CD3-91AB-6F1BB5738A3AQ35947894-E8FECE73-265C-4D64-9925-6DC54E08F51EQ35989209-03954411-7D18-4453-A32E-B0B47F1812BDQ36032570-2DD20CBA-2B60-4764-B5CB-A60F3B6C97B8Q36369631-FC3BCF5C-1F59-4848-B88C-7AE35EEF67DFQ36591005-D44037E3-A226-4F32-A17B-F3C5CDD9D14AQ37479685-0D0B5566-C99F-4ABC-AD7E-E9942EC62B1EQ37624395-B02F0D15-7BF0-4E97-AB32-66383422686CQ38649517-67B6C7EB-ED2E-4346-B185-1698130D86C7Q38853141-0E209418-E564-42F3-9C98-F72984FD51C3Q40080797-20BAC4B7-1171-4905-A6A6-9FE672DF41C8Q40087779-3D930C3D-7A3E-47A8-81AB-3805218C96A4Q40129444-E7FED9B1-F5DB-4924-AB06-6DFA5F5239B2Q40140395-85003861-4115-47D0-9259-435D30C554E2Q40163884-F9AEBF1C-B073-4D8A-9CE0-D0B9B340D930Q40231413-AB9BC5B2-F2DE-4D7B-98B0-D7945F4BDAE6Q40403121-3158490B-B218-436C-8263-1622C80B7AE0Q41925097-FD6A6F39-8098-462C-BC71-3F0181D9113DQ47549105-50149D0B-A37C-41DD-95A8-F1CCBF27031EQ48095992-D5E79AFB-E69C-4A91-B359-B6445E22AD9AQ48630939-6C7980E0-D708-4B8C-93FD-A212307ADD73Q53706343-C72D0A7B-4F8C-49B3-A986-B98385669F74Q55146328-6D9B4806-BAD7-4365-8C33-5CAE43E01619Q58751640-F929DB53-0A29-4873-82F1-82AFD5464417
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Vaccines for the 21st century
@ast
Vaccines for the 21st century
@en
Vaccines for the 21st century
@nl
type
label
Vaccines for the 21st century
@ast
Vaccines for the 21st century
@en
Vaccines for the 21st century
@nl
prefLabel
Vaccines for the 21st century
@ast
Vaccines for the 21st century
@en
Vaccines for the 21st century
@nl
P2093
P2860
P921
P3181
P356
P1476
Vaccines for the 21st century
@en
P2093
E. De Gregorio
R. Rappuoli
P2860
P304
P3181
P356
10.1002/EMMM.201403876
P407
P5008
P577
2014-05-06T00:00:00Z
2014-06-01T00:00:00Z